Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T31072
|
|||||
| Target Name |
Interleukine 12 (IL-12)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Psoriasis [ICD-11: EA90] | |||||
| 2 | Psoriatic arthritis [ICD-11: FA21] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
| 1 | ABP 654 | Drug Info | Phase 3 | Psoriatic arthritis | [2] | |
| 2 | Ad-RTS-hIL-12 | Drug Info | Phase 2 | Melanoma | [3] | |
| 3 | GEN-1 | Drug Info | Phase 2 | Ovarian cancer | [4], [5], [6] | |
| 4 | Tavokinogene telseplasmid | Drug Info | Phase 2 | Melanoma | [4], [7] | |
| 5 | M9241 | Drug Info | Phase 1 | Pancreatic cancer | [8] | |
| 6 | MEDI1191 | Drug Info | Phase 1 | Solid tumour/cancer | [9] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Replacement | [+] 5 Replacement drugs | + | ||||
| 1 | Ad-RTS-hIL-12 | Drug Info | [11] | |||
| 2 | GEN-1 | Drug Info | [12] | |||
| 3 | Tavokinogene telseplasmid | Drug Info | [1] | |||
| 4 | M9241 | Drug Info | [13] | |||
| 5 | MEDI1191 | Drug Info | [14] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540. | |||||
| REF 2 | ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health. | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476) | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 8 | ClinicalTrials.gov (NCT04327986) Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer. U.S. National Institutes of Health. | |||||
| REF 9 | ClinicalTrials.gov (NCT03946800) A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
| REF 10 | Clinical pipeline report, company report or official report of Amgen | |||||
| REF 11 | Clinical pipeline report, company report or official report of Ziopharm Oncology. | |||||
| REF 12 | Clinical pipeline report, company report or official report of Celsion. | |||||
| REF 13 | Clinical pipeline report, company report or official report of EMD Serono. | |||||
| REF 14 | Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. | |||||
| REF 15 | Clinical pipeline report, company report or official report of Biocytogen | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.